Ontology highlight
ABSTRACT:
SUBMITTER: Griesshammer M
PROVIDER: S-EPMC6097748 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Griesshammer Martin M Saydam Guray G Palandri Francesca F Benevolo Giulia G Egyed Miklos M Callum Jeannie J Devos Timothy T Sivgin Serdar S Guglielmelli Paola P Bensasson Caroline C Khan Mahmudul M Ronco Julian Perez JP Passamonti Francesco F
Annals of hematology 20180527 9
RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients without palpable splenomegaly. This analysis evaluated the durability of the efficacy and safety of ruxolitinib after patients completed the visit at week 80 or discontinued the study. Endpoints included proportion of patients achieving hematocrit control (< 45%), proportion of patients achieving compl ...[more]